.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Covington
Cerilliant
Dow
Argus Health
Baxter
Express Scripts
Accenture
Chubb

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,671,032

« Back to Dashboard

Which drugs does patent 7,671,032 protect, and when does it expire?


Patent 7,671,032 protects OLYSIO and is included in one NDA.

This patent has sixty-six patent family members in thirty-one countries.

Summary for Patent: 7,671,032

Title:HCV NS-3 serine protease inhibitors
Abstract: Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site. ##STR00001##
Inventor(s): Rosenquist; Asa (Huddinge, SE), Thorstensson; Fredrik (Linkoping, SE), Johansson; Per-Ola (Linkoping, SE), Kvarnstrom; Ingemar (Linkoping, SE), Samuelsson; Bertil (Huddinge, SE), Wallberg; Hans (Huddinge, SE)
Assignee: Medivir AB (Huddinge, SE)
Application Number:10/572,349
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Janssen Prods
OLYSIO
simeprevir sodium
CAPSULE;ORAL205123-001Nov 22, 2013RXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,671,032

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0400199Jan 30, 2004
Sweden0401288May 19, 2004
Sweden0402562Oct 22, 2004
PCT Information
PCT FiledJanuary 28, 2005PCT Application Number:PCT/SE2005/000097
PCT Publication Date:August 11, 2005PCT Publication Number: WO2005/073195

Non-Orange Book Patents for Patent: 7,671,032

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,608,590HCV NS-3 serine protease inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,671,032

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2552317► Subscribe
Canada2552319► Subscribe
China1914224► Subscribe
China1914225► Subscribe
Costa Rica8539► Subscribe
Costa Rica8540► Subscribe
Cyprus1109779► Subscribe
Germany602005017582► Subscribe
Denmark1713823► Subscribe
Germany602005019979► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Baxter
Chinese Patent Office
Teva
Mallinckrodt
Merck
Boehringer Ingelheim
Colorcon
Daiichi Sankyo
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot